An Open Label, Expanded Access Protocol Intended to Provide Treatment With MP-104 (Deflazacort) to U.S. Children, Adolescents, and/or Adults With Duchenne Muscular Dystrophy

Trial Profile

An Open Label, Expanded Access Protocol Intended to Provide Treatment With MP-104 (Deflazacort) to U.S. Children, Adolescents, and/or Adults With Duchenne Muscular Dystrophy

Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 12 Oct 2017

At a glance

  • Drugs Deflazacort (Primary) ; Deflazacort (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Expanded access; Registrational; Therapeutic Use
  • Sponsors PTC Therapeutics
  • Most Recent Events

    • 12 Oct 2017 Status changed from recruiting to completed, as reported in an abstract presented at the 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
    • 12 Oct 2017 Results (n=860) presented at the 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
    • 29 Oct 2015 Status changed from planning to recruiting, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top